血友病B型患者目前面临的挑战
Wolfgang Miesbach1, Annette von Drygalski2, Clive Smith3
1University Hospital Frankfurt, Frankfurt, Germany.
European journal of haematology
|December 12, 2023
概括
血友病B (HB) 治疗已通过复合因子IX (FIX) 产品得到改善,但仍然存在挑战. 需要新的治疗方法来解决正在进行的出血和所有HB患者的护理缺口.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病B (HB) 是一种罕见的,由于因子IX (FIX) 缺乏而导致的遗传性出血疾病.
- 目前的标准治疗包括终身FIX替代疗法,延长半衰期产品的进展.
- 尽管取得了进展,但在管理HB方面仍然存在重大挑战.
研究的目的:
- 为了回顾血友病B护理当前的挑战.
- 突出特定患者亚群的未满足需求.
- 确定需要提高意识和创新治疗策略的必要性.
主要方法:
- 对当前B型血友病治疗方法和挑战的文献综述.
- 对FIX替代疗法的疗效和局限性现有数据的分析.
- 检查不同HB群体的护理差异和未满足需求.
主要成果:
- 再组合FIX产品提高了安全性和可用性,但终身预防会带来坚持和访问问题.
- 延长半衰期的FIX产品提供了进步,但并不能消除所有挑战.
- 突破性出血,关节损伤以及女性,轻度至中度HB患者以及那些有抑制剂的患者的独特困难持续存在.
结论:
- 终身FIX替代疗法在获得,坚持和利用医疗保健方面带来了挑战.
- 在特定的B型血友病亚群中,持续存在低于最佳的结果和独特的困难.
- 对于严重的HB有极大需要提高认识,个性化护理和创新的治疗选择,以解决剩余的未满足需求.
相关概念视频
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Introduction to Hemostasis
8.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.0K
Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K
Rh Blood Group
1.5K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.5K
Pedigree Analysis
84.3K
Overview
84.3K


